Pentwater Capital Management LP Reports New 5.3% Stake in Centessa Pharmaceuticals plc

On May 15, 2026, Pentwater Capital Management LP and its principal, Matthew Halbower, filed a Schedule 13G disclosing a new 5.3% ownership stake in Centessa Pharmaceuticals plc (CNTA). The Reporting Persons beneficially own 8,170,000 ordinary shares, which are held in the form of American Depositary Shares (ADSs). Each ADS represents one ordinary share of the company. The filing indicates that these shares were acquired and are held in the ordinary course of business, without the intent to influence or change the control of the issuer. The ownership percentage is based on 154,568,531 ordinary shares outstanding as of March 17, 2026. Pentwater Capital Management LP serves as the investment manager to certain funds that directly hold the ADSs, while Matthew Halbower holds indirect beneficial ownership as the sole shareholder of the general partner of the investment manager. The reporting event occurred on March 31, 2026, marking a significant increase from a previously reported 0% position.